The Rollings Cancer Center (HCC) Clinical Trials Office (CTO) provides a centralized office for the conduct of cancer clinical trials at the Medical University of South Carolina (MUSC). The purpose of the HCC CTO is to provide an effective and efficient clinical research infrastructure to support investigators and clinicians in developing and implementing clinical research studies. The major functions of the CTO are to: Assist HCC Principal Investigators in the activation and administration of studies, including the preparations and communications required for scientific, ethical, financial and operational reviews as well as ongoing support for annual regulatory reviews Assist clinicians in screening and enrolling patients for clinical research studies Coordinate and ensure the completion of patient-specific study requirements Provide data management support for clinical research studies Prepare medical and research records for internal and external quality and compliance audits Provide training and education pertaining to the best practices in conducting clinical studies to clinical and CTO staff as well as new investigators Communicate the availability of clinical studies to HCC physicians, referring physicians and the public Administer the HCC Clinical Trials Network, which promotes statewide clinical trial access Over the past decade the CTO has expanded its capacity, services and capabilities and is considered one of MUSC's most effective and efficient clinical research units. Currently, the HCC CTO provides services to twenty-one MUSC departments/divisions and the clinical trials portfolio includes studies from all of the major NCI Cooperative Group trials (e.g., SWOG, RTOG, GOG, COG, ACRIN, ACoSOG, NSABP), industry sponsored studies and a growing number of investigator-initiated studies. Accrual to therapeutic clinical trials has quadrupled during the past five years and now represents 11% of total new HCC cancer cases.

Public Health Relevance

The HCC Clinical Trials Office provides key services that: 1) promote awareness of clinical studies and their importance to the future development of new therapies;2) ensure effective and efficient administration of clinical studies;and 3) facilitate the capture of information needed to disseminate the results of clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138313-05
Application #
8456111
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
5
Fiscal Year
2013
Total Cost
$122,255
Indirect Cost
$39,369
Name
Medical University of South Carolina
Department
Type
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Welch, Brandon M; Wiley, Kevin; Pflieger, Lance et al. (2018) Review and Comparison of Electronic Patient-Facing Family Health History Tools. J Genet Couns 27:381-391
Luque, John S; Tarasenko, Yelena N; Li, Hong et al. (2018) Utilization of Cervical Cancer Screening Among Hispanic Immigrant Women in Coastal South Carolina. J Racial Ethn Health Disparities 5:588-597
Panganiban, Clarisse H; Barth, Jeremy L; Darbelli, Lama et al. (2018) Noise-induced dysregulation of Quaking RNA binding proteins contributes to auditory nerve demyelination and hearing loss. J Neurosci :
Furukawa, Brian S; Pastis, Nicholas J; Tanner, Nichole T et al. (2018) Comparing Pulmonary Nodule Location During Electromagnetic Bronchoscopy With Predicted Location on the Basis of Two Virtual Airway Maps at Different Phases of Respiration. Chest 153:181-186
Vila├ža, Rita; Barros, Ivo; Matmati, Nabil et al. (2018) The ceramide activated protein phosphatase Sit4 impairs sphingolipid dynamics, mitochondrial function and lifespan in a yeast model of Niemann-Pick type C1. Biochim Biophys Acta Mol Basis Dis 1864:79-88
Pandey, Janardan P; Namboodiri, Aryan M; Armeson, Kent E et al. (2018) IGHG, IGKC, and FCGR genes and endogenous antibody responses to GARP in patients with breast cancer and matched controls. Hum Immunol 79:632-637
Mulligan, Jennifer K; Patel, Kunal; Williamson, Tucker et al. (2018) C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. Mucosal Immunol 11:1375-1385
Zhu, Yun; Wang, Cindy; Becker, Scott A et al. (2018) miR-145 Antagonizes SNAI1-Mediated Stemness and Radiation Resistance in Colorectal Cancer. Mol Ther 26:744-754
Tomko, Rachel L; Gray, Kevin M; Oppenheimer, Stephanie R et al. (2018) Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. Am J Drug Alcohol Abuse :1-16
Wolfe, A M; Dunlap, K M; Smith, A C et al. (2018) Myxoma Virus M083 Is a Virulence Factor Which Mediates Systemic Dissemination. J Virol 92:

Showing the most recent 10 out of 536 publications